Arcturus Therapeutics Holdings (ARCT) Change in Accured Expenses (2018 - 2026)

Arcturus Therapeutics Holdings (ARCT) has 9 years of Change in Accured Expenses data on file, last reported at -$1.2 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 85.04% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.3 million (down 77.53% YoY) and the FY2025 annual result came in at -$15.3 million, down 357.33% from the prior year.
• Change in Accured Expenses slipped to -$1.2 million in Q1 2026, from $4.5 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $9.4 million in Q2 2022 to a low of -$8.2 million in Q1 2025.
• A 5-year average of -$100647.1 and a median of -$454000.0 in 2023 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses surged 178.73% — and 2025, when it tumbled 2174.66%.
• Tracing ARCT's Change in Accured Expenses over 5 years: stood at $7.4 million in 2022, then plunged by 61.65% to $2.8 million in 2023, then soared by 130.15% to $6.6 million in 2024, then plunged by 32.09% to $4.5 million in 2025, then sank by 127.69% to -$1.2 million in 2026.
• The last three Change in Accured Expenses figures came in at -$1.2 million (Q1 2026), $4.5 million (Q4 2025), and -$5.4 million (Q3 2025), per Business Quant data.